Your state stopped covering your GLP-1. You still have options.

In 2026, six state Medicaid programs ended or let expire coverage of GLP-1 medications for weight loss, and Michigan cut its criteria to a BMI of 40 or higher. If you were on Wegovy, Zepbound, or Saxenda through Medicaid and got a letter ending your approval, this page explains exactly what happened, why it happened, and the four pathways that still work — starting with the one most patients never get told about.

What actually changed

Nothing about your body changed. A line item in a state budget changed. GLP-1 coverage for obesity is an optional Medicaid benefit, and optional benefits are the first thing states cut when spending climbs. Medicaid GLP-1 prescriptions grew roughly eightfold between 2019 and 2024, and states absorb a share of that cost directly. Massachusetts estimated it would save about $15 million a year by ending the benefit; its Medicaid director called the prices unsustainable while noting the state hopes to offer the drugs again if prices fall.

The national count peaked at 16 states in October 2025 and stands at 11 as of July 2026. North Carolina removed coverage in October 2025 and reinstated it nine weeks later — which is a genuine reason not to treat a denial as permanent.

Pathway 1 — check whether you already qualify under a covered indication

This is the pathway most patients miss. Medicaid must cover GLP-1s for their non-weight-loss FDA-approved indications in every state. If you have type 2 diabetes, established cardiovascular disease with overweight or obesity, moderate-to-severe obstructive sleep apnea with obesity, or noncirrhotic MASH with fibrosis, there is a coverage route in your state right now regardless of what the weight-loss policy says.

This matters enormously in midlife. The metabolic shift of perimenopause and postmenopause pushes women toward exactly these diagnoses: fasting insulin rises, HbA1c drifts up, blood pressure and lipids worsen, and sleep apnea becomes markedly more common after menopause. Many women who were treated as "weight loss patients" meet criteria for a covered condition and have simply never had the labs or the sleep study to document it.

What each covered indication requires

Pathway 2 — appeal the denial

Prior-authorization denials are appealable, and a meaningful share are overturned. Two arguments carry weight: the criteria applied do not match the state's current Preferred Drug List, or the clinical record supports a covered indication that was not evaluated. Ask for the specific criterion you failed in writing — states must tell you — and have your clinician respond to that criterion directly rather than resubmitting the same packet.

Pathway 3 — do not stop abruptly without a plan

Discontinuation typically brings regain of 50 to 70 percent of lost weight within a year, and appetite signaling returns within weeks. If continuation is not possible, the transition should be deliberate: protein intake at roughly 1.2 g/kg/day, resistance training two to three times weekly to protect the lean mass you kept, and a plan for the metabolic markers that improved on treatment. Stopping without that plan is how a coverage decision turns into a health outcome.

Pathway 4 — continuing outside Medicaid

Manufacturer direct-pay programs have lowered self-pay pricing substantially, and clinically supervised compounded therapy remains available through licensed 503A pharmacies for documented clinical need. Neither is right for everyone. What matters is comparing the real monthly number against what discontinuation costs you, rather than assuming continuation is out of reach.

Kindr's clinical team reviews your metabolic picture, tells you plainly whether a covered indication applies in your state, and lays out the continuation options that actually exist for you. Start with the state tracker, then bring what you find to a visit.

FAQ

Clinical sources

• KFF — Medicaid Coverage of and Spending on GLP-1s
• Stateline — More states consider dropping GLP-1 weight loss drugs from Medicaid
• 42 U.S.C. § 1396r-8 — Medicaid drug rebate program and permitted exclusions
• U.S. FDA — Wegovy (semaglutide 2.4 mg) Prescribing Information
• U.S. FDA — Zepbound (tirzepatide) Prescribing Information
• NEJM — Semaglutide 2.4 mg once weekly for weight management (STEP 1)
• NEJM — Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)

Related guides

Explore more

• The complete Menopause Guide
• HRT guide cluster
• Free symptom checker
• Pricing

Information on this page is for educational purposes only and is not a substitute for individualized medical advice. Prescription medications require clinical evaluation and provider approval. Individual results vary. This is not an emergency service — if you are experiencing a medical emergency, call 911.